Clinical trial design methodologies for advanced sarcoma therapy

References

• Constantinidou A, Pollack S, Loggers E, et al. The evolution of systemic therapy in sarcoma. Exp Rev Anticancer Ther 2013;13:211–23
   PubMed Web of Science ®Google Scholar
• Barretina J, Taylor BS, Banerji S, et al. Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet 2010;42:715–21
   PubMed Web of Science ®Google Scholar
• Wunder JS, Nielsen TO, Maki RG, et al. Opportunities for improving the therapeutic ratio for patients with sarcoma. Lancet Oncol 2007;8:513–24
   PubMed Web of Science ®Google Scholar
• Constantinidou A, Miah A, Pollack S, et al. New drugs and clinical trial design in advanced sarcoma: have we made any progress? Future Oncol 2013;9:1409–11
   PubMed Web of Science ®Google Scholar
• van der Graaf WTA, Blay J-Y, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012;379:1879–86
   PubMed Web of Science ®Google Scholar
• Maki RG, Wathen JK, Patel SR, et al. Randomized Phase II Study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of Sarcoma Alliance for Research Through Collaboration Study 002. J Clin Oncol 2007;25:2755–63
   PubMed Web of Science ®Google Scholar
• DeMatteo RP, Ballman KV, Antonescu CR, et al. Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) Intergroup Phase 2 Trial. Ann Surg 2013;258:422–9
   PubMed Web of Science ®Google Scholar
• Demetri GD, Reichardt P, Kang Y-K, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an International, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013;381:295–302
   PubMed Web of Science ®Google Scholar
• Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006;368:1329–38
   PubMed Web of Science ®Google Scholar
• Joensuu H, Eriksson M, Sundby Hall K, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA 2012;307:1265–72
   PubMed Web of Science ®Google Scholar
• George S, Feng Y, Manola J, et al. Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and/or progesterone receptors. Cancer 2014;120:738–43
   PubMed Web of Science ®Google Scholar
• Rutkowski P, Van Glabbeke M, Rankin CJ, et al. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two Phase II Clinical Trials. J Clin Oncol 2010;28:1772–9
   PubMed Web of Science ®Google Scholar
• Chawla S, Henshaw R, Seeger L, et al. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol 2013;14:901–8
   PubMed Web of Science ®Google Scholar
• Blanke CD, Rankin C, Demetri GD, et al. Phase III Randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008;26:626–32
   PubMed Web of Science ®Google Scholar
• Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004;364:1127–34
   PubMed Web of Science ®Google Scholar
• Lurkin A, Ducimetière F, Vince DR, et al. Epidemiological evaluation of concordance between initial diagnosis and central pathology review in a comprehensive and prospective series of sarcoma patients in the Rhone-Alpes region. BMC Cancer 2010;10:150
   PubMed Web of Science ®Google Scholar
• Schöffski P, Ray-Coquard IL, Cioffi A, et al. Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes. Lancet Oncol 2011;12:1045–52
   PubMed Web of Science ®Google Scholar
• Sleijfer S, Ray-Coquard I, Papai Z, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a Phase II Study from the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC Study 62043). J Clin Oncol 2009;27:3126–32
   PubMed Web of Science ®Google Scholar
• Ray-Coquard I, Blay J-Y, Italiano A, et al. Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. J Clin Oncol 2012;13:1133–40
   Google Scholar
• Pappo AS, Patel SR, Crowley J, et al. R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory ewing sarcoma family of tumors: results of a Phase II Sarcoma Alliance for Research Through Collaboration Study. J Clin Oncol 2011;29:4541–7
   PubMed Web of Science ®Google Scholar
• Tap WD, Demetri G, Barnette P, et al. Phase II Study of ganitumab, a fully human anti–type-1 insulin-like growth factor receptor antibody, in patients with metastatic ewing family tumors or desmoplastic small round cell tumors. J Clin Oncol 2012;30:1849–56
   PubMed Web of Science ®Google Scholar
• Demetri GD, Chawla SP, Ray-Coquard I, et al. Results of an International Randomized Phase III Trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy. J Clin Oncol 2013;31:2485–92
   PubMed Web of Science ®Google Scholar
• Ryan C, Schoffski P, Merimsky O, et al. PICASSO 3: a phase 3 International, randomized, double-blind, placebo-controlled study of doxorubicin (dox) plus palifosfamide (pali) vs. dox plus placebo for patients (pts) in first-line for metastatic soft tissue sarcoma (mSTS). Eur J Cancer 2013;49:S876
   Web of Science ®Google Scholar
• Amiri-Kordestani L, Fojo T. Why do phase iii clinical trials in oncology fail so often? J Natl Cancer Inst 2012;104:568–9
   PubMed Web of Science ®Google Scholar
• Pollack SM, Loggers ET, Rodler ET, et al. Immune-based therapies for sarcoma. Sarcoma 2011. DOI:438940.10.1155/2011/438940
   PubMedGoogle Scholar